MRI-guided Transurethral Ultrasound Ablation

DEVICE2 trials

Sponsors

Profound Medical Inc., Mayo Clinic

Conditions

Prostate CancerProstate CarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8

Unknown Phase

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

Active, not recruitingNCT02766543

Profound Medical Inc.Prostate Cancer

Start: 2016-09-21End: 2028-09-30Updated: 2025-08-17

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

RecruitingNCT05438563

Mayo ClinicProstate Carcinoma, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8

Start: 2022-04-06End: 2027-03-07Target: 100Updated: 2025-09-09

Related Papers

MP25-17 INITIAL EXPERIENCE WITH MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) IN MEN WITH LOCALIZED PROSTATE CANCER

The Journal of Urology2024-04-15

MP73-05 PIVOTAL STUDY OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: 4-YEAR FOLLOW UP

The Journal of Urology2023-03-231 citations

Deep learning prediction of non-perfused volume without contrast agents during prostate ablation therapy.

2022-11-082 citations